Evidence map›Paper›PMID 40923220›Full record

ArticleCancer medicine2025

Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist.

Kassem S Faraj, Mary Oerline, Samuel Kaufman, Avinash Maganty, Megan E V Caram, Vahakn B Shahinian, Brent K Hollenbeck

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kassem S FarajDow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-2130-0446
Mary OerlineDow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan, USA.
Samuel KaufmanDow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan, USA.
Avinash MagantyDow Division of Health Services Research, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0001-6436-6667
Megan E V CaramVA Health Services Research, Centers for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0003-1597-5428
Vahakn B ShahinianDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Brent K HollenbeckDepartment of Urology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Funding

Advanced Training in Urologic OncologyT32CA180984 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Ganesh S Palapattu, VAHAKN B SHAHINIAN · 2014 to 2026
$3.4M
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patientsR01CA275993 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLLENBECK, BRENT K., SHAHINIAN, VAHAKN B · 2023 to 2025
$2.5M
NCI NIH HHS CA275993NCI NIH HHS HS025707NCI NIH HHS R01 CA275993NCI NIH HHS T32 CA180984
6 · The paper itself

Abstract

introductionIn the past decade, the management of advanced prostate cancer has shifted to novel hormonal therapies. As a result, urologists have increased their involvement in the management of advanced prostate cancer. These therapies require close monitoring due to the possibility of adverse cardiometabolic events. We assessed outcomes among men diagnosed with advanced prostate cancer started on novel hormonal therapy by a urologist compared to those by a medical oncologist.

methodsWe performed a retrospective cohort study of Medicare beneficiaries with advanced prostate cancer treated with a novel hormonal therapy between 2012 and 2019. The primary outcome was an adverse event comprised of a hospital visit for a cardiometabolic event within 6 months of starting a novel hormonal therapy. Secondary outcomes included monthly out-of-pocket costs and treatment adherence.

resultsThere were 1212 (23%) and 4124 (77%) patients who were prescribed a novel hormonal therapy for the first time by a urologist and medical oncologist, respectively. No difference in the composite adverse event measure was observed in those managed by urologists or medical oncologists (4.2% vs. 4.7%, respectively, p = 0.49). Out-of-pocket costs, in men without low-income subsidies, did not vary by specialty ($772 vs. $790, p = 0.58). Adherence to treatment did not vary in men managed by urologists or medical oncologists (75% vs. 74%, respectively, p = 0.64).

conclusionsThe specialty of the physician prescribing a novel hormonal therapy was not associated with the risk of a cardiometabolic adverse event. Further, management by a urologist did not adversely affect costs to patients or adherence.

Indexed as

Androgen AntagonistsAntineoplastic Agents, HormonalOncologistsProstatic NeoplasmsUrologistsAgedAged, 80 and overHumansMaleMedicareRetrospective StudiesTreatment OutcomeUnited StatesAndrogen AntagonistsAntineoplastic Agents, Hormonaladverse eventsfinancial toxicityprostate cancerquality

Identifiers

PMID40923220
PMCPMC12417965

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.